253 related articles for article (PubMed ID: 15276093)
1. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
Rubenfire M;
Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis.
Insull W; McGovern ME; Schrott H; Thompson P; Crouse JR; Zieve F; Corbelli J
Arch Intern Med; 2004 May; 164(10):1121-7. PubMed ID: 15159270
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan.
Lin TH; Voon WC; Yen HW; Huang CH; Su HM; Lai WT; Sheu SH
Kaohsiung J Med Sci; 2006 Jun; 22(6):257-65. PubMed ID: 16793562
[TBL] [Abstract][Full Text] [Related]
4. Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease.
Hiatt WR; Hirsch AT; Creager MA; Rajagopalan S; Mohler ER; Ballantyne CM; Regensteiner JG; Treat-Jacobson D; Dale RA; Rooke T
Vasc Med; 2010 Jun; 15(3):171-9. PubMed ID: 20212073
[TBL] [Abstract][Full Text] [Related]
5. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin.
Gardner SF; Schneider EF; Granberry MC; Carter IR
Pharmacotherapy; 1996; 16(3):419-23. PubMed ID: 8726600
[TBL] [Abstract][Full Text] [Related]
7. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.
Hunninghake DB; McGovern ME; Koren M; Brazg R; Murdock D; Weiss S; Pearson T
Clin Cardiol; 2003 Mar; 26(3):112-8. PubMed ID: 12685616
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
Kashyap ML; McGovern ME; Berra K; Guyton JR; Kwiterovich PO; Harper WL; Toth PD; Favrot LK; Kerzner B; Nash SD; Bays HE; Simmons PD
Am J Cardiol; 2002 Mar; 89(6):672-8. PubMed ID: 11897208
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
Ballantyne CM; Davidson MH; McKenney J; Keller LH; Bajorunas DR; Karas RH
Am J Cardiol; 2008 May; 101(10):1428-36. PubMed ID: 18471454
[TBL] [Abstract][Full Text] [Related]
10. The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet.
Menon R; Tolbert D; Cefali E
Biopharm Drug Dispos; 2007 Sep; 28(6):297-306. PubMed ID: 17571283
[TBL] [Abstract][Full Text] [Related]
11. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin.
LaFleur J; Thompson CJ; Joish VN; Charland SL; Oderda GM; Brixner DI
Ann Pharmacother; 2006; 40(7-8):1274-9. PubMed ID: 16849622
[TBL] [Abstract][Full Text] [Related]
12. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
[TBL] [Abstract][Full Text] [Related]
13. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
[TBL] [Abstract][Full Text] [Related]
14. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ
Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381
[TBL] [Abstract][Full Text] [Related]
15. Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia.
Gupta EK; Ito MK
Heart Dis; 2002; 4(2):124-37. PubMed ID: 11975844
[TBL] [Abstract][Full Text] [Related]
16. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
Yim BT; Chong PH
Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
18. Extended-release niacin/lovastatin: the first combination product for dyslipidemia.
Bays HE
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):485-501. PubMed ID: 15225109
[TBL] [Abstract][Full Text] [Related]
19. Dosage, titration, and gaps in treatment with extended release niacin in clinical practice.
Kamal-Bahl SJ; Burke TA; Watson DJ; Wentworth CE
Curr Med Res Opin; 2008 Jun; 24(6):1817-21. PubMed ID: 18485268
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
